<?xml version='1.0' encoding='utf-8'?>
<document id="22490230"><sentence text="Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems." /><sentence text="The current studies assessed the utility of freshly plated hepatocytes, cryopreserved plated hepatocytes, and cryopreserved plated HepaRG cells for the estimation of inactivation parameters k(inact) and K(I) for CYP3A" /><sentence text=" This was achieved using a subset of CYP3A time-dependent inhibitors (fluoxetine, verapamil, clarithromycin, troleandomycin, and mibefradil) representing a range of potencies"><entity charOffset="70-80" id="DDI-PubMed.22490230.s3.e0" text="fluoxetine" /><entity charOffset="82-91" id="DDI-PubMed.22490230.s3.e1" text="verapamil" /><entity charOffset="93-107" id="DDI-PubMed.22490230.s3.e2" text="clarithromycin" /><entity charOffset="109-123" id="DDI-PubMed.22490230.s3.e3" text="troleandomycin" /><entity charOffset="129-139" id="DDI-PubMed.22490230.s3.e4" text="mibefradil" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e0" e2="DDI-PubMed.22490230.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e0" e2="DDI-PubMed.22490230.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e0" e2="DDI-PubMed.22490230.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e0" e2="DDI-PubMed.22490230.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e0" e2="DDI-PubMed.22490230.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e1" e2="DDI-PubMed.22490230.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e1" e2="DDI-PubMed.22490230.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e1" e2="DDI-PubMed.22490230.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e1" e2="DDI-PubMed.22490230.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e2" e2="DDI-PubMed.22490230.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e2" e2="DDI-PubMed.22490230.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e2" e2="DDI-PubMed.22490230.s3.e4" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e3" e2="DDI-PubMed.22490230.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22490230.s3.e3" e2="DDI-PubMed.22490230.s3.e4" /></sentence><sentence text=" The estimated k(inact) and K(I) values for each time-dependent inhibitor were compared with those obtained using human liver microsomes and used to estimate the magnitude of clinical pharmacokinetic drug-drug interaction (DDI)" /><sentence text=" The inactivation kinetic parameter, k(inact), was most consistent across systems tested for clarithromycin, verapamil, and troleandomycin, with a high k(inact) of 0"><entity charOffset="93-107" id="DDI-PubMed.22490230.s5.e0" text="clarithromycin" /><entity charOffset="109-118" id="DDI-PubMed.22490230.s5.e1" text="verapamil" /><entity charOffset="124-138" id="DDI-PubMed.22490230.s5.e2" text="troleandomycin" /><pair ddi="false" e1="DDI-PubMed.22490230.s5.e0" e2="DDI-PubMed.22490230.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22490230.s5.e0" e2="DDI-PubMed.22490230.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22490230.s5.e0" e2="DDI-PubMed.22490230.s5.e2" /><pair ddi="false" e1="DDI-PubMed.22490230.s5.e1" e2="DDI-PubMed.22490230.s5.e1" /><pair ddi="false" e1="DDI-PubMed.22490230.s5.e1" e2="DDI-PubMed.22490230.s5.e2" /></sentence><sentence text="91 min(-1) observed for mibefradil in HepaRG cells" /><sentence text=" The apparent K(I) estimates derived from the various systems displayed a range of variability from 3-fold for clarithromycin (5"><entity charOffset="111-125" id="DDI-PubMed.22490230.s7.e0" text="clarithromycin" /></sentence><sentence text="4-17" /><sentence text="7 μM) to 6-fold for verapamil (1" /><sentence text="9-12" /><sentence text="6 μM)" /><sentence text=" In general, the inactivation kinetic parameters derived from the cell systems tested fairly replicated what was observed in time-dependent inhibition studies using human liver microsomes" /><sentence text=" Despite some of the observed differences in inactivation kinetic parameters, the estimated DDIs derived from each of the tested systems generally agreed with the clinically reported DDI within approximately 2-fold" /><sentence text=" In addition, a plated cell approach offered the ability to conduct longer primary incubations (greater than 30 min), which afforded improved ability to identify the weak time-dependent inhibitor fluoxetine"><entity charOffset="196-206" id="DDI-PubMed.22490230.s14.e0" text="fluoxetine" /></sentence><sentence text=" Overall, results from these studies suggest that in vitro inactivation parameters generated from plated cell systems may be a practical approach for identifying time-dependent inhibitors and for estimating the magnitude of clinical DDIs" /><sentence text="" /></document>